Valerio Therapeutics Société anonyme (ALVIO.PA)
EUR 0.08
(3.31%)
EUR 0.08
(3.31%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 20.32 Million EUR | 12.92% |
| 2022 | 18.04 Million EUR | 94.75% |
| 2021 | 9.26 Million EUR | 0.23% |
| 2020 | 9.24 Million EUR | -53.16% |
| 2019 | 19.73 Million EUR | -8.45% |
| 2018 | 21.55 Million EUR | -71.35% |
| 2017 | 75.24 Million EUR | 179.36% |
| 2016 | 26.93 Million EUR | 6.39% |
| 2015 | 25.31 Million EUR | 12.79% |
| 2014 | 22.44 Million EUR | 34.91% |
| 2013 | 16.63 Million EUR | 9.7% |
| 2012 | 15.16 Million EUR | 75.97% |
| 2011 | 8.61 Million EUR | -54.82% |
| 2010 | 19.08 Million EUR | -15.63% |
| 2009 | 22.61 Million EUR | -27.17% |
| 2008 | 31.05 Million EUR | 34.16% |
| 2007 | 23.14 Million EUR | 65.86% |
| 2006 | 13.95 Million EUR | 109.06% |
| 2005 | 6.67 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 5.42 Million EUR | 6.21% |
| 2024 Q2 | 5.42 Million EUR | 0.0% |
| 2023 Q2 | 12.22 Million EUR | 114.2% |
| 2023 Q3 | 5.1 Million EUR | -58.2% |
| 2023 Q4 | 5.1 Million EUR | 0.0% |
| 2023 FY | 20.37 Million EUR | 12.92% |
| 2023 Q1 | 5.7 Million EUR | -22.48% |
| 2022 FY | 18.04 Million EUR | 94.75% |
| 2022 Q2 | 9.58 Million EUR | 112.6% |
| 2022 Q3 | 4.57 Million EUR | -52.31% |
| 2022 Q4 | 7.36 Million EUR | 61.03% |
| 2022 Q1 | 4.5 Million EUR | 12.64% |
| 2021 Q2 | 3.83 Million EUR | 59.74% |
| 2021 Q4 | 4 Million EUR | 105.65% |
| 2021 FY | 9.26 Million EUR | 0.23% |
| 2021 Q1 | 2.39 Million EUR | -16.57% |
| 2021 Q3 | 1.94 Million EUR | -49.23% |
| 2020 FY | 9.24 Million EUR | -53.16% |
| 2020 Q3 | 2.05 Million EUR | -28.43% |
| 2020 Q4 | 2.87 Million EUR | 39.92% |
| 2020 Q2 | 2.87 Million EUR | 4.7% |
| 2020 Q1 | 2.74 Million EUR | -25.64% |
| 2019 Q3 | 14.72 Million EUR | 103.5% |
| 2019 Q4 | 3.68 Million EUR | -74.94% |
| 2019 Q2 | 7.23 Million EUR | 51.9% |
| 2019 FY | 19.73 Million EUR | -8.45% |
| 2019 Q1 | 4.76 Million EUR | 108.04% |
| 2018 Q1 | 5.95 Million EUR | -80.48% |
| 2018 FY | 21.55 Million EUR | -71.35% |
| 2018 Q4 | 2.28 Million EUR | 0.0% |
| 2018 Q3 | 2.28 Million EUR | -61.54% |
| 2018 Q2 | 5.95 Million EUR | 0.0% |
| 2017 Q4 | 30.49 Million EUR | 0.0% |
| 2017 FY | 75.24 Million EUR | 179.36% |
| 2017 Q1 | 7.13 Million EUR | 0.05% |
| 2017 Q2 | 7.13 Million EUR | 0.0% |
| 2017 Q3 | 30.49 Million EUR | 327.68% |
| 2016 Q3 | 7.12 Million EUR | 12.0% |
| 2016 FY | 26.93 Million EUR | 6.39% |
| 2016 Q1 | 6.36 Million EUR | 4.69% |
| 2016 Q2 | 6.36 Million EUR | 0.0% |
| 2016 Q4 | 7.12 Million EUR | 0.0% |
| 2015 Q1 | 6.67 Million EUR | -3.76% |
| 2015 Q2 | 6.67 Million EUR | 0.0% |
| 2015 FY | 25.31 Million EUR | 12.79% |
| 2015 Q4 | 6.07 Million EUR | 0.0% |
| 2015 Q3 | 6.07 Million EUR | -8.94% |
| 2014 Q1 | 6.74 Million EUR | 62.99% |
| 2014 FY | 22.44 Million EUR | 34.91% |
| 2014 Q3 | 6.93 Million EUR | 2.75% |
| 2014 Q2 | 6.74 Million EUR | -0.0% |
| 2014 Q4 | 6.93 Million EUR | 0.0% |
| 2013 FY | 16.63 Million EUR | 9.7% |
| 2013 Q2 | 4.12 Million EUR | -0.0% |
| 2013 Q1 | 4.12 Million EUR | 0.0% |
| 2013 Q3 | 4.14 Million EUR | 0.47% |
| 2013 Q4 | 4.14 Million EUR | 0.0% |
| 2012 FY | 15.16 Million EUR | 75.97% |
| 2011 FY | 8.61 Million EUR | -54.82% |
| 2010 FY | 19.08 Million EUR | -15.63% |
| 2009 FY | 22.61 Million EUR | -27.17% |
| 2008 FY | 31.05 Million EUR | 34.16% |
| 2007 FY | 23.14 Million EUR | 65.86% |
| 2006 FY | 13.95 Million EUR | 109.06% |
| 2005 FY | 6.67 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.17 Million EUR | -386.474% |
| ABIVAX Société Anonyme | 127.37 Million EUR | 84.047% |
| Adocia SA | 15.62 Million EUR | -30.015% |
| Aelis Farma SA | 18.81 Million EUR | -7.976% |
| Biophytis S.A. | 14.33 Million EUR | -41.771% |
| Advicenne S.A. | 8.21 Million EUR | -147.352% |
| genOway Société anonyme | 16.73 Million EUR | -21.398% |
| IntegraGen SA | 5.35 Million EUR | -279.635% |
| Medesis Pharma S.A. | 1.56 Million EUR | -1198.758% |
| Neovacs S.A. | 10.34 Million EUR | -96.451% |
| NFL Biosciences SA | 4.37 Million EUR | -364.526% |
| Plant Advanced Technologies SA | 2.76 Million EUR | -634.94% |
| Quantum Genomics Société Anonyme | 1.71 Million EUR | -1082.795% |
| Sensorion SA | 27.05 Million EUR | 24.89% |
| Theranexus Société Anonyme | 3 Million EUR | -576.209% |
| TME Pharma N.V. | 5.49 Million EUR | -269.656% |
| Valbiotis SA | 9.86 Million EUR | -105.897% |
| TheraVet SA | 1.64 Million EUR | -1135.774% |
| argenx SE | 1.34 Billion EUR | 98.487% |
| BioSenic S.A. | 7.58 Million EUR | -167.968% |
| Celyad Oncology SA | 8.49 Million EUR | -139.34% |
| DBV Technologies S.A. | 89.4 Million EUR | 77.272% |
| Galapagos NV | 327.98 Million EUR | 93.805% |
| Genfit S.A. | 54.8 Million EUR | 62.922% |
| GeNeuro SA | 14.35 Million EUR | -41.531% |
| Hyloris Pharmaceuticals SA | 17.98 Million EUR | -12.97% |
| Innate Pharma S.A. | 64.57 Million EUR | 68.53% |
| Inventiva S.A. | 120.18 Million EUR | 83.093% |
| MaaT Pharma SA | 21.59 Million EUR | 5.917% |
| MedinCell S.A. | 32.92 Million EUR | 38.278% |
| Nanobiotix S.A. | 58.92 Million EUR | 65.517% |
| Onward Medical N.V. | 20.64 Million EUR | 1.574% |
| Oryzon Genomics S.A. | 18.49 Million EUR | -9.855% |
| OSE Immunotherapeutics SA | 23.58 Million EUR | 13.858% |
| Oxurion NV | 12.21 Million EUR | -66.366% |
| Pharming Group N.V. | 204.24 Million EUR | 90.051% |
| Poxel S.A. | 28.76 Million EUR | 29.359% |
| GenSight Biologics S.A. | 32.66 Million EUR | 37.783% |
| Transgene SA | 31.23 Million EUR | 34.936% |
| Financière de Tubize SA | 114.38 Thousand EUR | -17663.946% |
| UCB SA | 2.94 Billion EUR | 99.309% |
| Valneva SE | 134.92 Million EUR | 84.94% |
| Vivoryon Therapeutics N.V. | 24.69 Million EUR | 17.706% |